RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.